Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daylong is a brand of dermatological sunscreen products, originally developed by Spirig Pharma and later acquired by Galderma. These products are formulated as liposomal lotions, gels, or fluids, providing broad-spectrum protection against UVA, UVB, and sometimes infrared (IR) radiation. They are designed for various skin types, including sensitive skin, and are characterized by high SPF, water resistance, and photostability. Daylong sunscreens often incorporate moisturizing and nourishing ingredients such as aloe vera and vitamin E, and are indicated for preventing sun-induced skin damage, photoaging, and reducing the risk of skin cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daylong.